Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8234 results

  1. Iptacopan for treating primary IgA nephropathy [ID6640]

    Awaiting development Reference number: GID-TA11844 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. MolecuLight i:X for wound imaging

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Digital AI tools in histopathology (breast and prostate cancer)

    Awaiting development Reference number: GID-HTE10087 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  5. Digital tools and platforms to support the early detection and initial diagnosis of hearing loss

    Awaiting development Reference number: GID-HTE10088 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  6. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

    NICE guideline
    In development

  7. Retatrutide for managing overweight and obesity [ID6644]

    Awaiting development Reference number: GID-TA11845 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Digital flexor tenotomy for diabetic foot

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  18 March 2026

    Technology appraisal guidance
    In development

  10. Dermal allograft augmentation in proximal humerus fracture fixation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

    Awaiting development Reference number: GID-TA11744 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    Awaiting development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development